The trial of the oral drug was stopped after data showed the pill’s high efficacy in reducing the risk of developing Covid-19 in a severe form
Pfizer said its experimental pill to treat Covid-19 reduced the risk of hospitalization or death in treated patients by 89%.
The trial of the oral drug was discontinued after data showed the pill’s high efficacy in reducing the risk of developing Covid-19 in a severe form.
The results appear to surpass those seen with the oral drug manufactured by Merck & Co-MSD and approved – for the moment – only in the UK. In fact, the data had shown that Merck-MSD’s molnupiravir can halve the risk of developing severe disease.
Currently no data is available: Pfizer said it plans to submit the results of the treatment – which includes the pill in combination with another older antiviral, ritonavir, to the US Food and Drug Administration.
The combined treatment, which will be marketed under the name Paxlovid, consists of three pills administered twice a day.
Article being updated …
November 5, 2021 (change November 5, 2021 | 12:11)
© REPRODUCTION RESERVED
#Pfizer #AntiCovid #pill #effective #reducing #risk #hospitalization #death